Volume 15, Issue 4, Pages 478-484 (April 2018) Dofetilide dose reductions and discontinuations in women compared with men Sean D. Pokorney, MD, MBA, Debbie C. Yen, PharmD, Kristen B. Campbell, PharmD, Nancy M. Allen LaPointe, PharmD, MHS, Shubin Sheng, MS, Laine Thomas, PhD, Tristram D. Bahnson, MD, FHRS, James P. Daubert, MD, FHRS, Jonathan P. Picini, MD, MHS, FHRS, Kevin P. Jackson, MD, Kevin L. Thomas, MD, Sana M. Al-Khatib, MD, MHS, FHRS Heart Rhythm Volume 15, Issue 4, Pages 478-484 (April 2018) DOI: 10.1016/j.hrthm.2018.01.027 Copyright © 2018 Heart Rhythm Society Terms and Conditions
Figure 1 Dofetilide discontinuations or dose reductions by sex. The P values represent the statistical difference between the prevalence in women and the prevalence in men. Heart Rhythm 2018 15, 478-484DOI: (10.1016/j.hrthm.2018.01.027) Copyright © 2018 Heart Rhythm Society Terms and Conditions
Figure 2 Dofetilide dose at discharge by sex. The bars represent the proportion of women and men who were discharged on the respective dofetilide doses. The doses are all twice daily doses. Heart Rhythm 2018 15, 478-484DOI: (10.1016/j.hrthm.2018.01.027) Copyright © 2018 Heart Rhythm Society Terms and Conditions